Response to treatment after initial treatment
| . | SAA . | VSAA . |
|---|---|---|
| 3 months | ||
| Evaluable | 84 | 117 |
| CR | 9* | 6† |
| PR | 40* | 40† |
| NR | 35 | 71 |
| Alive | 34 | 71 |
| Dead | 1 | 0 |
| 6 months | ||
| Evaluable | 83 | 115 |
| CR | 17‡ | 20§ |
| PR | 38‡ | 63§ |
| NR | 28 | 32 |
| Alive | 27 | 31 |
| Dead | 1 | 1 |
| . | SAA . | VSAA . |
|---|---|---|
| 3 months | ||
| Evaluable | 84 | 117 |
| CR | 9* | 6† |
| PR | 40* | 40† |
| NR | 35 | 71 |
| Alive | 34 | 71 |
| Dead | 1 | 0 |
| 6 months | ||
| Evaluable | 83 | 115 |
| CR | 17‡ | 20§ |
| PR | 38‡ | 63§ |
| NR | 28 | 32 |
| Alive | 27 | 31 |
| Dead | 1 | 1 |
Data are numbers (%) of responders.
NR indicates no response.
*These classes combined were 58% to the total number.
†These classes combined were 39% to the total number.
‡These classes combined were 66% to the total number.
§These classes combined were 72% to the total number